What the FDA labels say about taking them together
Olanzapine and selegiline
Selegiline's FDA label (Zelapar) of June 1, 2021 names olanzapine in its warnings and precautions section; the olanzapine labels PlainMeds reads (3) do not name selegiline. The selegiline label: “… MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and olanzapine (Zydis) selegiline (ZELAPAR).”
Check it at the source: the olanzapine FDA label on DailyMed (effective March 5, 2026, Macleods Pharmaceuticals Limited); the selegiline FDA label on DailyMed (effective August 7, 2024, Rising Pharma Holdings, Inc.).
What does the olanzapine label say about selegiline?
Olanzapine's label (effective March 5, 2026) and its 2 other brand-application labels do not name selegiline in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Olanzapine), Macleods Pharmaceuticals Limited, effective March 5, 2026 (SPL set 8e095987-bdea-42f2-9550-c7155cf07d30), via openFDA; the full label on DailyMed
What does the selegiline label say about olanzapine?
Zelapar label (Bausch Health US, LLC, June 1, 2021), warnings and precautionsSerotonin syndrome and hyperpyrexia have been reported with the combined treatment of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a non-selective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and olanzapine (Zydis) selegiline (ZELAPAR).
Emsam label (Viatris Specialty LLC, May 15, 2020), drug interactionsNo dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole).
Source: FDA drug label (Zelapar, NDA021479), Bausch Health US, LLC, effective June 1, 2021 (SPL set 380d7717-2a79-42f3-a712-efe5e7696ba0), via openFDA
Source: FDA drug label (Emsam, NDA021336), Viatris Specialty LLC, effective May 15, 2020 (SPL set b891bd9f-fdb8-4862-89c5-ecdd700398a3), via openFDA
Source: FDA drug label (Selegiline Hydrochloride), Rising Pharma Holdings, Inc., effective August 7, 2024 (SPL set 23c4481f-d150-40c6-addb-b3e454ca914f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Olanzapine | Selegiline | |
|---|---|---|
| Labeled for | Schizophrenia, Bipolar disorder, Depression | Parkinson's disease, Depression |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.147 per tablet 20 mg tablet | $0.756 per capsule 5 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once